Cost-effectiveness of testing Hepatitis B-positive pregnant women for Hepatitis B e antigen or viral load

Obstetrics and Gynecology

Volumn 123, Issue 5, 2014, Pages 929-937

  Fan, Lin ^a   Owusu Edusei Jr , Kwame ^a   Schillie, Sarah F ^a   Murphy, Trudy V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GESTATIONAL AGE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN INFECTION; PASSIVE IMMUNIZATION; PERINATAL INFECTION; POINT OF CARE TESTING; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; VIRUS LOAD; VIRUS TRANSMISSION; ANTIBIOTIC PROPHYLAXIS; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; PREGNANCY; PREVENTION AND CONTROL; SEROLOGY; TRANSMISSION; VACCINATION; VERTICAL TRANSMISSION;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, PASSIVE; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; QUALITY-ADJUSTED LIFE YEARS; SEROLOGIC TESTS; VACCINATION; VIRAL LOAD;

EID: 84900397445     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000124     Document Type: Article

References (50)

1. Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. Am J Obstet Gynecol 2012;207: 231.e1-7.
2. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics 2012;129: 609-16.
3. Din ES, Wasley A, Jacques-Carroll L, Sirotkin B, Wang S. Estimating the number of births to hepatitis B virus-infected women in 22 states, 2006. Pediatr Infect Dis J 2011;30: 575-9.
4. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis-B virus transmission by immunization. An economic-analysis of current recommendations. JAMA 1995;274: 1201-8.
5. Krarup H, Andersen S, Madsen PH, Christensen PB, Laursen AL, Bentzen-Petersen A, et al; DANHEP group. HBeAg and not genotypes predicts viral load in patients with hepatitis B in Denmark: a nationwide cohort study. Scand J Gastroenterol 2011;46: 1484-91.
6. Ott JJ, Stevens GA, Wiersma ST. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012;12: 131.
7. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012;19: e18-25.
8. Shi ZJ, Yang YB, Ma L, Li XM, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus a systematic review and meta-analysis. Obstet Gynecol 2010;116: 147-59.
9. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341: 1256-63.
10. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012;57: 2423-9.
11. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, et al. Telbivudine prevents vertical transmission from HBeAgpositive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10: 520-6.
12. Martin JA, Hamilton BE, Ventura SJ, Osterman MJK, Wilson EC, Mathews TJ. Births: final data for 2010. Natl Vital Stat Rep 2012;61: 1-72.
13. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al; Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54: 1-31.
14. Hoerger TJ, Schillie S, Wittenborn JS, Bradley CL, Zhou F, Byrd K, et al. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care 2013;36: 63-9.
15. United States life tables, 2008. Available at: www.cdc.gov. Retrieved December 1, 2013.
16. Nguyen G, Garcia RT, Nguyen N, Trinh H, Keeffe EB, Nguyen MH. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009;29: 755-64.
17. Kerkar N. Hepatitis B in children: complexities in management. Pediatr Transpl 2005;9: 685-91.
18. Unal ER, Lazenby GB, Lintzenich AE, Simpson KN, Newman R, Goetzl L. Cost-effectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission. Obstet Gynecol 2011;118: 655-62.
19. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010;202: 192-201.
20. Lee CF, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systemic review and meta-analysis. BMJ 2006;332: 328-36.
21. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al. Yeast-recombinant hepatitis-B vaccine. Efficacy with hepatitis-B immune globulin in prevention of perinatal hepatitis-B virus transmission. JAMA 1987;257: 2612-6.
22. Shi ZJ, Li XM, Ma L, Yang YB. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-tochild transmission - a meta-analysis. Int J Infect Dis 2010;14: e622-34.
23. Xiao XM, Li AZ, Chen X, Zhu YK, Miao J. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynecol Obstet 2007; 96: 167-70.
24. Wheeley SM, Jackson PT, Boxall EH, Tarlow MJ, Gatrad AR, Anderson J, et al. Prevention of perinatal transmission of hepatitis-B virus (HBV): a comparison 2 prophylactic schedules. J Med Virol 1991;35: 212-5.
25. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190: 489-92.
26. Yuan J, Lin J, Xu A, Li H, Hu B, Chen J, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat 2006;13: 597-604.
27. Hung HF, Chen HH. Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection. Pharmacoeconomics 2011;29: 1063-73.
28. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012;10: 452-9.
29. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011; 17: 4321-33.
30. Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis 2011;52: 1294-306.
31. Hu YQ, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, et al. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med 2008;35: 25-32.
32. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a costeffectiveness analysis. Am J Gastroenterol 2006;101: 2076-89.
33. Kim SY, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med 2006;30: 498-506.
34. Post SE, Sodhi NK, Peng CH, Wan KJ, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) 2011;30: 340-8.
35. Sawyer MH, Hoerger TJ, Murphy TV, et al. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP) (reprinted from MMWR, vol 60, pg 1709-1711, 2011). JAMA 2012;307: 659-62.
36. Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 2011;29: 3270-7.
37. Consumer price indexes - all urban consumers. Bureau of Labor Statistics, United States Department of Labor, 2011. Available at: http://www.bls.gov/cpi/ home.htm. Retrieved May 5, 2013.
38. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost- Effectiveness in Health and Medicine. JAMA 1996;276: 1339-41.
39. Buchanan C, Tran TT. Management of chronic hepatitis B in pregnancy. Clin Liver Dis 2010;14: 495-504.
40. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
41. Yim HJ, Lok ASF. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43(suppl 1):S173-81.
42. Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003;9: 1501-3.
43. Brown RS, Verna EC, Pereira MR, Pereira MR, Tilson HH, Aguilar C, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the antiretroviral pregnancy registry. J Hepatol 2012;57: 953-9.
44. Honkoop P, de Man RA, Niesters HGM, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32: 635-9.
45. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008;15: 37-41.
46. Giles ML, Visvanathan K, Lewin SR, Sasadeusz J. Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv 2012;67: 37-44.
47. Keeffe EB, Dieterich DT, Han SHB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4: 936-62.
48. Smith EA. Postvaccination serologic testing results for infants aged #24 months exposed to hepatitis B virus at birth - United States, 2008-2011. MMWR Morb Mortal Wkly Rep 2012;61: 768-71.
49. Beasley RP, Hwang LY, Lee GCY, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis-B virus-infections with hepatitis-B immune globulin and hepatitis-B vaccine. Lancet 1983;2: 1099-102.
50. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004;38(suppl 3):S144-7.